advertisement
Abstract #78488 Published in IGR 20-1
Patient stratification in clinical glaucoma trials using the individual tear proteome
Nättinen J; Jylhä A; Aapola U; Parkkari M; Mikhailova A; Beuerman RW; Uusitalo HScientific reports 2018; 8: 12038
Glaucoma patients are prone to concomitant ocular surface diseases; however, switching from preserved to preservative-free medication can often alleviate these symptoms. The objective of this study was to examine how the adverse effects and tear proteome change for glaucoma patients (n = 28) during a 12-month drug switch from preserved latanoprost (Xalatan) to preservative-free tafluprost (Taflotan). We hypothesized that patient stratification could help identify novel recovery patterns in both tear proteomics and clinical data. In order to accomplish patient stratification, we implemented sequential window acquisition of all theoretical mass spectrometry (SWATH-MS) as a tool for quantitative analysis of individual tear protein profiles. During each visit (baseline and four follow-up visits), the patients' tears were sampled and the state of their ocular surface was evaluated clinically. Altogether 785 proteins were quantified from each tear sample using SWATH strategy and as these protein expression levels were compared between baseline and 12-month follow-up, three distinct patient groups were identified. We evaluated how these patient groups differed in their protein expression levels at baseline and discovered that the patients with increased levels of pro-inflammatory proteins and decreased levels of protective proteins benefitted most from the medication switch.
SILK, Department of Ophthalmology, Faculty of Medicine and Life Sciences and BioMediTech, University of Tampere, Tampere, Finland. janika.nattinen@uta.fi.
Full articleClassification:
3.12 Proteomics (Part of: 3 Laboratory methods)
